 |
|
|
|
February 2001 Cover
|
|
Vertex Pharmaceuticals reported that a fast-track prodrug of the HIV protease inhibitor Agenerase, VX-175, is now in phase III tests. The product was formulated for a dosing regimen of three pills two times a day;
however, the new tests-- in which all patients will receive Ziagen and Epivir twice daily-- will also explore once-a-day dosing. One of the phase III studies, which will last 48 weeks, will compare VX- 175 given under the new
dosing regimen to Viracept administered twice daily to 210 antiretroviral-naive patients. In the second study, more than 600 patients who have not previously taken antiretroviral drugs will be randomized to receive either three
VX-175 tablets and Norvir once a day or 1,250 mg of Viracept twice a day for 48 weeks.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
